Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Biomx Inc PHGE

Healthcare Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer... see more

NYSEAM:PHGE - Post Discussion

Biomx Inc > BiomX Announces Entry into Merger Agreement with Adaptive Ph
View:
Post by whytestocks on Mar 06, 2024 10:15am

BiomX Announces Entry into Merger Agreement with Adaptive Ph

Just In: $PHGE BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million FinancingAcquisition will create phage therapy company with an advanced pipeline with two P hase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ( “ CF ” ) patients and BX 2 11 for the treatment of diabetic foot...PHGE - BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Be the first to comment on this post
Biomx Inc